Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical Trial
Objective: In this study, we primarily evaluated the effects of IMMUPHYLA LCW23 on symptoms of allergic rhinitis. IMMUPHYLA LCW23 is a commercial probiotic product containing the Lactobacillus paracasei LCW23 strain. Materials and Methods: Sixty 5–18-year-old children with allergic rhinitis positive...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-10-01
|
| Series: | Pediatric Respirology and Critical Care Medicine |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/prcm.prcm_2_22 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850177301887582208 |
|---|---|
| author | Chung-Bin Huang Ying-Hsiang Wang Wei-Jen Chen Chih-Ming Tsai Chia-Hao Kang Pai-Yin Lin Hsin-I Lo Hong-Ren Yu |
| author_facet | Chung-Bin Huang Ying-Hsiang Wang Wei-Jen Chen Chih-Ming Tsai Chia-Hao Kang Pai-Yin Lin Hsin-I Lo Hong-Ren Yu |
| author_sort | Chung-Bin Huang |
| collection | DOAJ |
| description | Objective:
In this study, we primarily evaluated the effects of IMMUPHYLA LCW23 on symptoms of allergic rhinitis. IMMUPHYLA LCW23 is a commercial probiotic product containing the Lactobacillus paracasei LCW23 strain.
Materials and Methods:
Sixty 5–18-year-old children with allergic rhinitis positive for the dust mite-specific bivalent antibody and meeting the inclusion criteria were enrolled in this double-blind, randomized, placebo-controlled trial. They were administered 2–4 g of the probiotic product containing L. paracasei LCW23 (2.5 × 109 cells/g; n = 28) or a placebo supplement (n = 32) according to their body weights for 12 weeks. After the treatment period, a self-assessment of allergic rhinitis symptoms in the nose and eyes was performed.
Results:
This study results revealed that 12-week supplementation with IMMUPHYLA LCW23 is safe, with no side effects. In addition, the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) assessment revealed that the probiotic significantly alleviated general discomfort (P = 0.003) and common symptoms of allergic rhinitis, such as nasal congestion (P = 0.033), runny nose (P = 0.001), and blowing nose (P = 0.008).
Conclusion:
Administration of IMMUPHYLA LCW23 was safe in the long-term follow-up study. The probiotic likely reduced the risk of allergy prevalence, without any major side effects. |
| format | Article |
| id | doaj-art-2a29286a3ce14280a7f808853eb0867b |
| institution | OA Journals |
| issn | 2543-0343 2543-0351 |
| language | English |
| publishDate | 2021-10-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Pediatric Respirology and Critical Care Medicine |
| spelling | doaj-art-2a29286a3ce14280a7f808853eb0867b2025-08-20T02:18:59ZengWolters Kluwer Medknow PublicationsPediatric Respirology and Critical Care Medicine2543-03432543-03512021-10-0154626910.4103/prcm.prcm_2_22Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical TrialChung-Bin HuangYing-Hsiang WangWei-Jen ChenChih-Ming TsaiChia-Hao KangPai-Yin LinHsin-I LoHong-Ren YuObjective: In this study, we primarily evaluated the effects of IMMUPHYLA LCW23 on symptoms of allergic rhinitis. IMMUPHYLA LCW23 is a commercial probiotic product containing the Lactobacillus paracasei LCW23 strain. Materials and Methods: Sixty 5–18-year-old children with allergic rhinitis positive for the dust mite-specific bivalent antibody and meeting the inclusion criteria were enrolled in this double-blind, randomized, placebo-controlled trial. They were administered 2–4 g of the probiotic product containing L. paracasei LCW23 (2.5 × 109 cells/g; n = 28) or a placebo supplement (n = 32) according to their body weights for 12 weeks. After the treatment period, a self-assessment of allergic rhinitis symptoms in the nose and eyes was performed. Results: This study results revealed that 12-week supplementation with IMMUPHYLA LCW23 is safe, with no side effects. In addition, the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) assessment revealed that the probiotic significantly alleviated general discomfort (P = 0.003) and common symptoms of allergic rhinitis, such as nasal congestion (P = 0.033), runny nose (P = 0.001), and blowing nose (P = 0.008). Conclusion: Administration of IMMUPHYLA LCW23 was safe in the long-term follow-up study. The probiotic likely reduced the risk of allergy prevalence, without any major side effects.https://journals.lww.com/10.4103/prcm.prcm_2_22allergic rhinitisheat-killed probioticimmuphyla lcw23lactobacillus paracasei lcw23prqlq |
| spellingShingle | Chung-Bin Huang Ying-Hsiang Wang Wei-Jen Chen Chih-Ming Tsai Chia-Hao Kang Pai-Yin Lin Hsin-I Lo Hong-Ren Yu Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical Trial Pediatric Respirology and Critical Care Medicine allergic rhinitis heat-killed probiotic immuphyla lcw23 lactobacillus paracasei lcw23 prqlq |
| title | Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical Trial |
| title_full | Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical Trial |
| title_fullStr | Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical Trial |
| title_full_unstemmed | Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical Trial |
| title_short | Efficacy and Safety of Orally Administered Heat-Killed Lactobacillus Paracasei LCW23 in Patients with Allergic Rhinitis: A Randomized Controlled Clinical Trial |
| title_sort | efficacy and safety of orally administered heat killed lactobacillus paracasei lcw23 in patients with allergic rhinitis a randomized controlled clinical trial |
| topic | allergic rhinitis heat-killed probiotic immuphyla lcw23 lactobacillus paracasei lcw23 prqlq |
| url | https://journals.lww.com/10.4103/prcm.prcm_2_22 |
| work_keys_str_mv | AT chungbinhuang efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial AT yinghsiangwang efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial AT weijenchen efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial AT chihmingtsai efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial AT chiahaokang efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial AT paiyinlin efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial AT hsinilo efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial AT hongrenyu efficacyandsafetyoforallyadministeredheatkilledlactobacillusparacaseilcw23inpatientswithallergicrhinitisarandomizedcontrolledclinicaltrial |